Cargando…
Current status and perspectives in immunotherapy for metastatic melanoma
Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in th...
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844761/ https://www.ncbi.nlm.nih.gov/pubmed/29552325 http://dx.doi.org/10.18632/oncotarget.23746 |
| _version_ | 1783305300616413184 |
|---|---|
| author | Marconcini, Riccardo Spagnolo, Francesco Stucci, Luigia Stefania Ribero, Simone Marra, Elena Rosa, Francesco De Picasso, Virginia Di Guardo, Lorenza Cimminiello, Carolina Cavalieri, Stefano Orgiano, Laura Tanda, Enrica Spano, Laura Falcone, Alfredo Queirolo, Paola |
| author_facet | Marconcini, Riccardo Spagnolo, Francesco Stucci, Luigia Stefania Ribero, Simone Marra, Elena Rosa, Francesco De Picasso, Virginia Di Guardo, Lorenza Cimminiello, Carolina Cavalieri, Stefano Orgiano, Laura Tanda, Enrica Spano, Laura Falcone, Alfredo Queirolo, Paola |
| author_sort | Marconcini, Riccardo |
| collection | PubMed |
| description | Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation. |
| format | Online Article Text |
| id | pubmed-5844761 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Impact Journals LLC |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-58447612018-03-16 Current status and perspectives in immunotherapy for metastatic melanoma Marconcini, Riccardo Spagnolo, Francesco Stucci, Luigia Stefania Ribero, Simone Marra, Elena Rosa, Francesco De Picasso, Virginia Di Guardo, Lorenza Cimminiello, Carolina Cavalieri, Stefano Orgiano, Laura Tanda, Enrica Spano, Laura Falcone, Alfredo Queirolo, Paola Oncotarget Review Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation. Impact Journals LLC 2018-01-03 /pmc/articles/PMC5844761/ /pubmed/29552325 http://dx.doi.org/10.18632/oncotarget.23746 Text en Copyright: © 2018 Marconcini et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
| spellingShingle | Review Marconcini, Riccardo Spagnolo, Francesco Stucci, Luigia Stefania Ribero, Simone Marra, Elena Rosa, Francesco De Picasso, Virginia Di Guardo, Lorenza Cimminiello, Carolina Cavalieri, Stefano Orgiano, Laura Tanda, Enrica Spano, Laura Falcone, Alfredo Queirolo, Paola Current status and perspectives in immunotherapy for metastatic melanoma |
| title | Current status and perspectives in immunotherapy for metastatic
melanoma |
| title_full | Current status and perspectives in immunotherapy for metastatic
melanoma |
| title_fullStr | Current status and perspectives in immunotherapy for metastatic
melanoma |
| title_full_unstemmed | Current status and perspectives in immunotherapy for metastatic
melanoma |
| title_short | Current status and perspectives in immunotherapy for metastatic
melanoma |
| title_sort | current status and perspectives in immunotherapy for metastatic
melanoma |
| topic | Review |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844761/ https://www.ncbi.nlm.nih.gov/pubmed/29552325 http://dx.doi.org/10.18632/oncotarget.23746 |
| work_keys_str_mv | AT marconciniriccardo currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT spagnolofrancesco currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT stucciluigiastefania currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT riberosimone currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT marraelena currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT rosafrancescode currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT picassovirginia currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT diguardolorenza currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT cimminiellocarolina currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT cavalieristefano currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT orgianolaura currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT tandaenrica currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT spanolaura currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT falconealfredo currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT queirolopaola currentstatusandperspectivesinimmunotherapyformetastaticmelanoma AT currentstatusandperspectivesinimmunotherapyformetastaticmelanoma |